Carolyn Revta

1.7k total citations
33 papers, 850 citations indexed

About

Carolyn Revta is a scholar working on Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health and Physiology. According to data from OpenAlex, Carolyn Revta has authored 33 papers receiving a total of 850 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pediatrics, Perinatology and Child Health, 8 papers in Public Health, Environmental and Occupational Health and 8 papers in Physiology. Recurrent topics in Carolyn Revta's work include Palliative Care and End-of-Life Issues (7 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Dementia and Cognitive Impairment Research (5 papers). Carolyn Revta is often cited by papers focused on Palliative Care and End-of-Life Issues (7 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Dementia and Cognitive Impairment Research (5 papers). Carolyn Revta collaborates with scholars based in United States, Canada and China. Carolyn Revta's co-authors include Paul G. Richardson, Vincent T. Ho, Robert J. Soiffer, Joseph H. Antin, Nancy A. Kernan, Paul Martin, Massimo Iacobelli, Eva C. Guinan, Sergio Giralt and Amrita Krishnan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Carolyn Revta

30 papers receiving 829 citations

Peers

Countries citing papers authored by Carolyn Revta

Since Specialization

Citations

This map shows the geographic impact of Carolyn Revta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carolyn Revta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carolyn Revta more than expected).

Fields of papers citing papers by Carolyn Revta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carolyn Revta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carolyn Revta. The network helps show where Carolyn Revta may publish in the future.

Co-authorship network of co-authors of Carolyn Revta

This figure shows the co-authorship network connecting the top 25 collaborators of Carolyn Revta. A scholar is included among the top collaborators of Carolyn Revta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carolyn Revta. Carolyn Revta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease 2025 ·Alzheimer s Research & Therapy ·Yuqi Qiu, Diane M. Jacobs, Karen Messer, David P. Salmon, Cheryl L. Wellington, Sophie Stukas, Carolyn Revta, James Brewer, Gabriel C. Léger, (unknown), (unknown), Stephen Kaplita, Vladimir Coric, Irfan Qureshi, Howard Feldman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients 2024 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Dawn Matthews, Jefferson W. Kinney, Aaron Ritter, Randolph D. Andrews, (unknown), Ana Lukić, (unknown), Carolyn Revta, Howard Fillit, Kate Zhong, Babak Tousi, James B. Leverenz, Howard Feldman, Jeffrey L. Cummings	6
3	Asian Cohort for Alzheimer Disease (ACAD) Pilot Study 2024 ·Alzheimer Disease & Associated Disorders ·Guerry M. Peavy, (unknown), Carolyn Revta, (unknown), (unknown), (unknown), (unknown), Li‐San Wang, Howard Feldman	0
4	Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam) 2024 ·PLoS ONE ·Howard Feldman, José A. Luchsinger, Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Steven D. Edland, Karen Messer, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Kevin E. Yarasheski, Philip B. Verghese, (unknown), Henrik Zetterberg, (unknown), (unknown), Gary E. Gibson, (unknown)	1
5	Successful Recruitment of Vietnamese Americans into the Asian Cohort for Alzheimer’s Disease (ACAD) Pilot Study at UC San Diego 2022 ·Alzheimer s & Dementia ·(unknown), Van Ta Park, Guerry M. Peavy, (unknown), (unknown), Marian Tzuang, Carolyn Revta, Diep N. Nguyen, (unknown), (unknown), (unknown), Howard Feldman	1
6	Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia 2021 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Dawn Matthews, Aaron Ritter, Ronald G. Thomas, Randolph D. Andrews, Ana Lukić, Carolyn Revta, Jefferson W. Kinney, Babak Tousi, James B. Leverenz, Howard Fillit, Kate Zhong, Howard Feldman, Jeffrey L. Cummings	32
7	Longitudinal investigation for enhancing Down Syndrome Research (LIFE‐DSR) Study: Tau PET and CSF sub‐studies 2021 ·Alzheimer s & Dementia ·James A. Hendrix, Angela Britton, Bradley T. Christian, (unknown), Michael Egan, Howard Feldman, Suzanne Hendrix, W. Joseph Herring, Matthew Kennedy, Jessie Nicodemus‐Johnson, Carolyn Revta, Arie Struyk, Cyrille Sur, William C. Mobley	2
8	Patient-Controlled Analgesia for Cancer-Related Pain: Clinical Predictors of Patient Outcomes 2017 ·Journal of the National Comprehensive Cancer Network ·Emily J. Martin, Eric Roeland, (unknown), Carolyn Revta, James D. Murphy, Katherine E. Fero, Heidi N. Yeung	6
9	Transfusion practices at end of life for hematopoietic stem cell transplant patients 2017 ·Supportive Care in Cancer ·(unknown), D. Joseph, Sandahl H. Nelson, Carolyn Revta, (unknown), Carolyn Mulroney, Eric Roeland	6
10	Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials 2016 ·Supportive Care in Cancer ·Eric Roeland, D. Joseph, Sandahl H. Nelson, Tyler M. Seibert, Susan Heavey, Carolyn Revta, (unknown), Vickie E. Baracos	32
11	Lack of Documentation of Evidence-Based Prognostication in Cancer Patients by Inpatient Palliative Care Consultants 2015 ·Journal of Palliative Medicine ·Andrew Bruggeman, Susan Heavey, D. Joseph, Carolyn Revta, Eric Roeland	4
12	Novel investigational biologics for the treatment of cancer cachexia 2014 ·Expert Opinion on Biological Therapy ·D. Joseph, Susan Heavey, Carolyn Revta, Eric Roeland	17
13	Pilot study to evaluate a novel advance-care planning tool to identify informed health care proxies in an oncology palliative care clinic. 2014 ·Journal of Clinical Oncology ·Eric Roeland, (unknown), Susan Heavey, (unknown), Carolyn Revta, Rabia S. Atayee, D. Joseph	1
14	Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation 2012 ·Expert Review of Hematology ·Selim Corbacioglu, Nancy A. Kernan, Leslie Lehmann, Joel A. Brochstein, Carolyn Revta, Stephan A. Grupp, Paul Martin, Paul G. Richardson	29
15	Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury 2010 ·Biology of Blood and Marrow Transplantation ·Corey Cutler, Haesook T. Kim, (unknown), Gary Bradwin, Carolyn Revta, Julie Aldridge, Vincent T. Ho, Edwin P. Alyea, John Koreth, Philippe Armand, Robert J. Soiffer, Jerome Ritz, Paul G. Richardson, Joseph H. Antin	60
16	Use of defibrotide in the treatment and prevention of veno-occlusive disease 2009 ·Expert Review of Hematology ·Paul G. Richardson, Erica Linden, Carolyn Revta, Vincent T. Ho	10
17	Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome 2009 ·Biology of Blood and Marrow Transplantation ·Jason Coppell, Paul G. Richardson, Robert J. Soiffer, Paul Martin, Nancy A. Kernan, Allen Chen, Eva C. Guinan, Georgia B. Vogelsang, Amrita Krishnan, Sergio Giralt, Carolyn Revta, Nicole A. Carreau, Massimo Iacobelli, Enric Carreras, Tapani Ruutu, Tiziano Barbui, Joseph H. Antin, Dietger Niederwieser	367
18	Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Review and Update on the Use of Defibrotide 2007 ·Seminars in Thrombosis and Hemostasis ·Vincent T. Ho, Erica Linden, Carolyn Revta, (unknown)	25
19	Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies 2007 ·Bone Marrow Transplantation ·Vincent T. Ho, Carolyn Revta, Paul G. Richardson	74
20	Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial. 2006 ·Blood ·Paul G. Richardson, Robert J. Soiffer, Joseph H. Antin, Zhezhen Jin, Joanne Kurtzberg, (unknown), Gideon Steinbach, Karen F. Murray, G. B. Vogelsang, (unknown), A. Krishnan, Nancy A. Kernan, David Avigan, TR Spitzer, D Warren, Carolyn Revta, Lan Wei, Massimo Iacobelli, GB McDonald, Eva C. Guinan	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact